Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 9k
3 June 2020
E-003352/2020
Question for written answer
to the Commission
Rule 138
Joanna Kopcińska (ECR)
 Subject: The pharmaceutical strategy for Europe

The pharmaceutical strategy for Europe sets out six key challenges, and points out that one of the initiatives addresses the issue of medicine shortages. These shortages often involve off-patent medicines such as antibiotics, cancer therapies and vaccines. The current COVID-19 pandemic has clearly shown that Europe is dependent on third countries when it comes to the production and supply of medicines, putting Europe at risk of shortages and exacerbating existing supply problems.

It is noted in the roadmap that the Commission will be conducting regular exchanges of views with the relevant committees in the European Parliament.

1. In the draft roadmap, the Commission states that ‘[t]he pharmaceutical strategy will examine the need for legislative and non-legislative actions and EU investments’. How is the Commission planning to step up and support EU production capacity as regards active ingredients and pharmaceutical starting materials (key elements of the strategic chemical and pharmaceutical production chain), in particular in the light of the current pandemic and the myriad complications that have affected the supply of essential medicines to patients in Europe?

2. How is the Commission planning to stimulate the development of EU investment in various programmes such as Horizon Europe (i.e. research funding, investment in research and development, European partnerships with industry), InvestEU and the Digital Europe programme? What impact will the pharmaceutical strategy have on all the research and development partnerships in the area of healthcare, and how will it steer them towards the development of a COVID-19 vaccine?

Original language of question: PL
Last updated: 18 June 2020Legal notice - Privacy policy